Relay Therapeutics Inc (RLAY) USD0.001
Sell:$3.10Buy:$3.22
$0.01
(0.31%)
- This stock can be held in a
Stocks and Shares ISA$0.01
(0.31%)$0.01
(0.31%)Company Information
About this company
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
Key people
Key facts
- EPICRLAY
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS75943R1023
- Market cap$527.21m
- Employees261
- Shares in issue169.52m
- ExchangeNASDAQ
- IndexTR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.